Edwards Lifesciences Corporation $EW Shares Sold by Amiral Gestion

Amiral Gestion lessened its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 57.5% during the first quarter, HoldingsChannel reports. The firm owned 96,389 shares of the medical research company’s stock after selling 130,321 shares during the quarter. Edwards Lifesciences accounts for approximately 4.3% of Amiral Gestion’s investment portfolio, making the stock its 10th largest holding. Amiral Gestion’s holdings in Edwards Lifesciences were worth $7,719,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in EW. Elo Mutual Pension Insurance Co boosted its holdings in shares of Edwards Lifesciences by 39.9% in the 3rd quarter. Elo Mutual Pension Insurance Co now owns 89,674 shares of the medical research company’s stock valued at $6,974,000 after purchasing an additional 25,562 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Edwards Lifesciences by 27.3% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 109,749 shares of the medical research company’s stock valued at $9,356,000 after buying an additional 23,514 shares during the period. Assenagon Asset Management S.A. increased its holdings in shares of Edwards Lifesciences by 39.6% during the 4th quarter. Assenagon Asset Management S.A. now owns 2,286,298 shares of the medical research company’s stock worth $194,907,000 after buying an additional 648,870 shares during the last quarter. Central Pacific Bank Trust Division acquired a new stake in shares of Edwards Lifesciences during the 4th quarter worth $775,000. Finally, Stance Capital LLC raised its position in shares of Edwards Lifesciences by 373.1% in the 3rd quarter. Stance Capital LLC now owns 45,994 shares of the medical research company’s stock worth $3,577,000 after buying an additional 36,272 shares during the period. Institutional investors and hedge funds own 79.46% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on EW shares. Evercore reiterated an “outperform” rating and issued a $93.00 target price on shares of Edwards Lifesciences in a report on Friday, April 24th. Barclays restated an “overweight” rating and set a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a research note on Monday, April 27th. TD Cowen restated a “buy” rating and issued a $104.00 price objective (up from $97.00) on shares of Edwards Lifesciences in a report on Tuesday, June 2nd. Canaccord Genuity Group set a $85.00 price objective on Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, April 24th. Finally, Mizuho set a $95.00 target price on Edwards Lifesciences and gave the stock an “outperform” rating in a report on Monday, April 13th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $95.96.

Insider Buying and Selling

In related news, CFO Scott B. Ullem sold 13,000 shares of the firm’s stock in a transaction dated Thursday, April 9th. The stock was sold at an average price of $80.04, for a total transaction of $1,040,520.00. Following the sale, the chief financial officer directly owned 39,699 shares in the company, valued at approximately $3,177,507.96. This trade represents a 24.67% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of the business’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the transaction, the senior vice president directly owned 15,334 shares in the company, valued at $1,319,950.72. This trade represents a 3.57% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 81,038 shares of company stock worth $6,683,255 over the last three months. 0.31% of the stock is currently owned by corporate insiders.

Edwards Lifesciences Stock Performance

NYSE:EW opened at $86.98 on Wednesday. The firm’s fifty day simple moving average is $83.70 and its 200 day simple moving average is $83.16. The company has a current ratio of 4.42, a quick ratio of 3.63 and a debt-to-equity ratio of 0.06. Edwards Lifesciences Corporation has a twelve month low of $72.30 and a twelve month high of $89.60. The firm has a market capitalization of $50.08 billion, a price-to-earnings ratio of 46.27, a PEG ratio of 2.15 and a beta of 0.87.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, April 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.73 by $0.05. Edwards Lifesciences had a return on equity of 15.19% and a net margin of 17.39%.The firm had revenue of $1.65 billion during the quarter, compared to the consensus estimate of $1.60 billion. During the same period in the prior year, the firm earned $0.64 EPS. The firm’s quarterly revenue was up 16.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2026 guidance at 2.950-3.050 EPS and its Q2 2026 guidance at 0.700-0.760 EPS. As a group, equities research analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.